---
title: "BCPE Perseus Investor Takes Activist Stake at Kailera Therapeutics with 20.3% Stake"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/283906549.md"
description: "BCPE Perseus Investor, LP has acquired a 20.3% stake in Kailera Therapeutics, Inc., which includes pre-IPO preferred shares and additional shares purchased on April 20, 2026. This investment grants Bain Capital’s affiliate significant influence, as it plans to actively collaborate with the company's management and board on various initiatives. Andrew Kaplan from Bain Capital already serves on the board, facilitating direct engagement. The investor may adjust its holdings over time, reflecting its commitment to ongoing performance and strategy reviews."
datetime: "2026-04-23T23:36:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/283906549.md)
  - [en](https://longbridge.com/en/news/283906549.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/283906549.md)
---

# BCPE Perseus Investor Takes Activist Stake at Kailera Therapeutics with 20.3% Stake

BCPE Perseus Investor, LP disclosed a 20.3% stake in Kailera Therapeutics, Inc. common stock. The position reflects pre-IPO preferred shares that converted at the IPO and an additional 8.4 million shares purchased on April 20, 2026. The move gives Bain Capital’s affiliate significant influence alongside its existing board representation.

**Investor Intent**

BCPE Perseus Investor says it will "take an active role in working with the Issuer's management and the Board on operational, financial and strategic initiatives." Andrew Kaplan, a Partner at Bain Capital Investors, already sits on Kailera Therapeutics’ board, positioning the firm to engage directly on priorities.

The investor may change the size of its holding over time and could buy more shares or sell part of its position as it evaluates the company’s progress. It describes the stake as an investment and plans ongoing reviews of performance and strategy.

**Investor's Background**

BCPE Perseus Investor, LP is a Delaware limited partnership affiliated with Bain Capital Fund XIV and managed through Bain Capital Investors, LLC. Bain Capital is a global private investment firm known for active ownership across private equity, credit, and healthcare-focused investments. The firm often partners with management teams to drive operating improvements and long-term growth.

Original SEC Filing: Kailera Therapeutics, Inc. \[ KLRA \] - SCHEDULE 13D - Apr. 23, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [KLRA.US](https://longbridge.com/en/quote/KLRA.US.md)

## Related News & Research

- [Jefferies Sticks to Their Buy Rating for Kailera Therapeutics, Inc. (KLRA)](https://longbridge.com/en/news/287949963.md)
- [TD Cowen Reaffirms Their Buy Rating on Kailera Therapeutics, Inc. (KLRA)](https://longbridge.com/en/news/287719655.md)
- [Applied Aerospace & Defense, Inc. Announces Launch of Initial Public Offering | AADX Stock News](https://longbridge.com/en/news/287627979.md)
- [Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates | KLRA Stock News](https://longbridge.com/en/news/287673757.md)
- [Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge](https://longbridge.com/en/news/288152232.md)